Vancomycin TDM Simulator
Indication: Bacterial infections
Therapeutic drug monitoring simulator for vancomycin. AUC-guided dosing (target 400-600), CrCL-based clearance, therapeutic range overlay.
Drug Overview
Clinical Context
- Drug Class
- Glycopeptide
- Therapeutic Area
- Infectious Disease
- Indication
- Bacterial infections
- Route of Administration
- IV
Model Information
- Model Type
- popPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
🎯 AUC-Based Vancomycin Dosing: IDSA/ASHP 2020 Guidelines
Target AUC₀₋₂₄: 400-600 mg·h/L
The 2020 consensus guidelines from the Infectious Diseases Society of America (IDSA) and American Society of Health-System Pharmacists (ASHP) recommend targeting an AUC₀₋₂₄ of 400-600 mg·h/L for serious MRSA infections. This target is based on:
- Improved efficacy: AUC/MIC ≥400 correlates with better clinical outcomes
- Reduced nephrotoxicity: Lower AUC targets reduce kidney injury risk vs. high trough-based dosing (trough 15-20 mg/L)
- Better PK/PD target: AUC/MIC ratio is the most predictive pharmacodynamic index for vancomycin efficacy
What is AUC/MIC?
AUC/MIC is the ratio of the 24-hour area under the concentration-time curve (AUC₀₋₂₄) to the minimum inhibitory concentration (MIC) of the pathogen:
For MRSA with MIC ≤1 mg/L, targeting AUC₀₋₂₄ 400-600 mg·h/L achieves the optimal AUC/MIC ratio of 400-600. Higher MIC values may require dose adjustments or alternative therapy.
Clinical Context
Vancomycin is a glycopeptide antibiotic primarily used for serious gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Traditional trough-only monitoring (targeting 15-20 mg/L) was associated with increased nephrotoxicity without proven efficacy benefit. The shift to AUC-guided dosing represents a paradigm change in vancomycin therapeutic drug monitoring.
🧠 Population PK & Bayesian Estimation
This vancomycin TDM simulator uses a population pharmacokinetics (PopPK) model with Bayesian estimation — a sophisticated approach that combines:
What Makes This Different from Simple Calculators?
PopPK models incorporate data from thousands of patients, capturing how factors like age, weight, renal function, and disease state influence vancomycin clearance and volume of distribution.
When you enter 1-2 measured vancomycin concentrations, the Bayesian algorithm updates the population estimates with your patient's actual data, providing individualized PK parameters and more accurate AUC predictions.
Unlike trough-only calculators, PopPK models simulate the entire concentration-time curve, allowing accurate AUC calculation regardless of when samples are drawn (peak, trough, or random times).
This is why the IDSA/ASHP 2020 guidelines explicitly recommend using Bayesian software tools or published AUC estimation equations — simple first-order kinetic calculators cannot adequately capture the complexity of vancomycin pharmacokinetics across diverse patient populations.
⚖️ PopPK Simulator vs. Simple Calculators
Understanding the difference between population pharmacokinetic modeling and basic dosing calculators:
| Feature | PKPDBuilder PopPK Simulator | Simple Trough-Based Calculators |
|---|---|---|
| Modeling Approach | Population PK with Bayesian estimation | First-order kinetic equations |
| AUC Calculation | Full AUC₀₋₂₄ from concentration-time curve | Estimated from trough only (less accurate) |
| Patient Covariates | Age, weight, CrCl, albumin, disease state | Basic (weight, CrCl only) |
| Sample Timing Flexibility | Any time (peak, trough, random) | Requires steady-state trough |
| Interindividual Variability | Accounts for population variability (IIV) | Fixed population averages |
| Guideline Alignment | ✅ IDSA/ASHP 2020 recommended approach | ❌ Outdated trough-only method |
| Clinical Accuracy | Higher (captures complex PK behavior) | Lower (oversimplified assumptions) |
| Use Case | Research, education, TDM optimization | Quick estimates (less reliable) |
Note: While this simulator uses advanced PopPK modeling, it is for educational and research purposes only. Clinical dosing decisions should be made using validated clinical software (e.g., InsightRx, DoseMeRx) and in consultation with clinical pharmacists and infectious disease specialists.
About This Simulator
This interactive pharmacokinetic simulator for Vancomycin TDM allows you to explore concentration-time profiles under different dosing scenarios. The underlying popPK model characterizes the pharmacokinetics of this glycopeptide following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the target AUC for vancomycin?
According to the 2020 IDSA/ASHP vancomycin therapeutic monitoring guidelines, the target AUC₀₋₂₄ (area under the concentration-time curve over 24 hours) is 400-600 mg·h/L for serious MRSA infections. This AUC/MIC ratio target of 400-600 (assuming MIC ≤1 mg/L) is associated with improved clinical outcomes and reduced nephrotoxicity risk compared to traditional trough-based monitoring.
How to calculate vancomycin AUC/MIC?
Vancomycin AUC/MIC is calculated by dividing the 24-hour area under the concentration-time curve (AUC₀₋₂₄) by the minimum inhibitory concentration (MIC) of the pathogen. For example, if AUC₀₋₂₄ = 500 mg·h/L and MIC = 1 mg/L, then AUC/MIC = 500. The target AUC/MIC ratio for vancomycin is ≥400 for optimal bactericidal activity against MRSA. This simulator uses population pharmacokinetics and Bayesian estimation to calculate individualized AUC values based on patient-specific factors and measured drug concentrations.
What are the vancomycin dosing guidelines per IDSA/ASHP 2020?
The 2020 IDSA/ASHP consensus guidelines recommend AUC-guided dosing instead of trough-only monitoring. For empiric dosing, adults typically receive 15-20 mg/kg every 8-12 hours (not to exceed 2 grams per dose). The goal is to achieve an AUC₀₋₂₄ of 400-600 mg·h/L. Population pharmacokinetic modeling with Bayesian estimation is the preferred method for AUC calculation, using 1-2 concentration measurements taken at steady state.
Why is AUC-based monitoring better than trough-based monitoring for vancomycin?
AUC-based monitoring is superior because: (1) AUC/MIC ratio is a better predictor of vancomycin efficacy than trough levels alone, (2) targeting AUC 400-600 mg·h/L reduces nephrotoxicity risk compared to high trough targets (15-20 mg/L), (3) population PK models with Bayesian estimation provide more accurate exposure estimates than simple trough-based calculations, and (4) the IDSA/ASHP 2020 guidelines explicitly recommend transitioning from trough monitoring to AUC-guided dosing for improved patient outcomes.
What is the Vancomycin TDM PK simulator?
This is a free, interactive pharmacokinetic simulator for Vancomycin TDM used in Bacterial infections. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Vancomycin TDM belong to?
Vancomycin TDM is classified as a Glycopeptide. It is used in the Infectious Disease therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Vancomycin TDM. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a popPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Voriconazole
Invasive aspergillosis, candidemia
Oxfendazole Population PK — Tablet Formulation in Healthy African Adults
Onchocerciasis (river blindness)
Shingrix (Recombinant Zoster Vaccine) PK Simulator
Shingles prevention
Prevnar 20 (PCV20) PK Simulator
Pneumococcal disease prevention
Paxlovid (Nirmatrelvir/Ritonavir) PK Simulator
COVID-19 treatment
Gardasil 9 (9-valent HPV Vaccine) PK Simulator
HPV-related cancer prevention
Ready to Simulate?
Launch the Vancomycin TDM simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community